Quick Answer
Kraig Biocraft Laboratories, Inc. reported Total Revenue of $401.6 thousand for fiscal year 2018.
Kraig Biocraft Laboratories, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Revenue (ASC 606) | — | — | — | — | — | — |
| Net Income | -$3.62M -6.6% |
-$3.40M -12.2% |
-$3.03M +21.1% |
-$3.84M +52.2% |
-$8.05M -61.8% |
-$4.97M -70.8% |
| Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total Assets | $2.57M +70.4% |
$1.51M -53.4% |
$3.23M -29.3% |
$4.57M +51.3% |
$3.02M +136.6% |
$1.28M +70.1% |
| Cash and Equivalents | $1.79M +165.9% |
$673.3K -73.6% |
$2.55M -33.9% |
$3.86M | — | — |
| Stockholders Equity | -$8.00M +1.8% |
-$8.15M -42.8% |
-$5.71M -62.0% |
-$3.52M +33.5% |
-$5.30M +19.4% |
-$6.57M -22.0% |
| R&D Expense | $165.8K +0.8% |
$164.4K -30.9% |
$237.9K +34.8% |
$176.4K -10.8% |
$197.7K +123.5% |
$88.5K -60.3% |
| Operating Income | -$3.37M -9.8% |
-$3.07M -17.6% |
-$2.61M -23.3% |
-$2.12M +23.1% |
-$2.76M +39.1% |
-$4.53M -72.9% |
| Shares Outstanding | — | — | — | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2021 | $0.00 | — | — |
| Revenue (ASC 606) | June 30, 2021 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$1.51M | -248.5% | +0.0% |
| Diluted EPS | September 30, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $2.36M | +16.3% | +48.1% |
| Cash and Equivalents | September 30, 2025 | $1.57M | +31.6% | +99.3% |
| Stockholders Equity | September 30, 2025 | -$7.96M | -8.1% | +6.1% |
| R&D Expense | September 30, 2025 | $9.2K | -63.0% | -85.5% |
| Operating Income | September 30, 2025 | -$1.43M | -238.3% | -124.8% |
| Shares Outstanding | March 31, 2019 | 835.73M | +2.3% | +2.3% |
- Kraig Biocraft Laboratories, Inc. reported Total Revenue of $401.6 thousand for fiscal year 2018.
- Kraig Biocraft Laboratories, Inc. showed an increase of +312.7% in Total Revenue compared to the prior fiscal year.
- Kraig Biocraft Laboratories, Inc. reported Revenue (ASC 606) of $401.6 thousand for fiscal year 2018.
- Kraig Biocraft Laboratories, Inc. reported Net Income of -$3.62 million for fiscal year 2025.
- Kraig Biocraft Laboratories, Inc. showed a decrease of -6.6% in Net Income compared to the prior fiscal year.
- Kraig Biocraft Laboratories, Inc. reported Diluted EPS of $0.00 per share for fiscal year 2025.
- Kraig Biocraft Laboratories, Inc. reported Total Assets of $2.57 million for fiscal year 2025.
- Kraig Biocraft Laboratories, Inc. showed an increase of +70.4% in Total Assets compared to the prior fiscal year.
- Kraig Biocraft Laboratories, Inc. reported Cash and Equivalents of $1.79 million for fiscal year 2025.
- Kraig Biocraft Laboratories, Inc. showed an increase of +165.9% in Cash and Equivalents compared to the prior fiscal year.
- Kraig Biocraft Laboratories, Inc. reported Stockholders Equity of -$8.00 million for fiscal year 2025.
- Kraig Biocraft Laboratories, Inc. showed an increase of +1.8% in Stockholders Equity compared to the prior fiscal year.
- Kraig Biocraft Laboratories, Inc. reported R&D Expense of $165.8 thousand for fiscal year 2025.
- Kraig Biocraft Laboratories, Inc. showed an increase of +0.8% in R&D Expense compared to the prior fiscal year.
- Kraig Biocraft Laboratories, Inc. reported Operating Income of -$3.37 million for fiscal year 2025.
- Kraig Biocraft Laboratories, Inc. showed a decrease of -9.8% in Operating Income compared to the prior fiscal year.
- Kraig Biocraft Laboratories, Inc. reported Shares Outstanding of 773.63 million shares for fiscal year 2016.
- Kraig Biocraft Laboratories, Inc. showed an increase of +9.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: